# Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

> **NCT02360579** · PHASE2 · COMPLETED · sponsor: **Iovance Biotherapeutics, Inc.** · enrollment: 220 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** Lifileucel

## Key facts

- **NCT ID:** NCT02360579
- **Lead sponsor:** Iovance Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-24
- **Primary completion:** 2024-10-24
- **Final completion:** 2024-10-24
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02360579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02360579, "Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02360579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*